The rise of Ozempic and Wegovy, two medications containing semaglutide, has sparked a surge in poison control calls, raising concerns about their misuse and mishandling. This trend is particularly intriguing given the drugs' recent approval for weight management, a shift from their original use for diabetes treatment. Jordan Miller, an undergraduate student at UT San Antonio, delves into this phenomenon, collaborating with researchers to analyze national poison control data. The findings reveal a dramatic increase in calls post-FDA approval, with semaglutide cases dominating. This surge is attributed to the misuse and mishandling of the drug, as patients often take it daily instead of weekly and start with the highest dose, leading to preventable dosing mistakes. The research highlights the need for better patient education and improved prescribing practices to prevent these errors. The study's impact extends beyond statistics, emphasizing the role of data science in uncovering public health trends and informing meaningful action. As the popularity of Ozempic and Wegovy continues to grow, so does the importance of understanding and addressing the potential risks associated with their use.
